CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE)
CSL (OTC:CSLLY) said its Broadmeadows, Australia plasma fractionation facility was named Overall Winner of the 2025 Facility of the Year Award by ISPE on Oct 26, 2025. The purpose-built plant uses Pharma 4.0 principles, advanced automation, real-time monitoring, robotics and a digital twin to enable flexible, paperless, multi-process manufacturing.
CSL reported the facility increased plasma processing capacity nine-fold to handle over 10 million litres annually, and cited modular design, reusable filters, energy-efficient systems and a fully automated robotic warehouse.
CSL (OTC:CSLLY) ha dichiarato che il suo stabilimento di frazionamento del plasma a Broadmeadows, Australia, è stato nominato Vincitore assoluto del 2025 Facility of the Year Award da ISPE il 26 ottobre 2025. L'impianto costruito su misura utilizza i principi Pharma 4.0, automazione avanzata, monitoraggio in tempo reale, robotica e un gemello digitale per abilitare una produzione flessibile, senza carta e multi-processo.
CSL ha riferito che l'impianto ha aumentato la capacità di lavorazione del plasma nove volte, per gestire oltre 10 milioni di litri all'anno, citando design modulare, filtri riutilizzabili, sistemi a basso consumo energetico e un magazzino robotizzato completamente automatizzato.
CSL (OTC:CSLLY) dijo que su instalación de fraccionamiento de plasma en Broadmeadows, Australia, fue nombrada Ganador General del Premio Facility of the Year 2025 por ISPE el 26 de octubre de 2025. La planta de uso específico utiliza principios Pharma 4.0, automatización avanzada, monitoreo en tiempo real, robótica y un gemelo digital para permitir una fabricación flexible, sin papel y multi-proceso.
CSL informó que la instalación aumentó la capacidad de procesamiento de plasma nueve veces para manejar más de 10 millones de litros anuales, y citó diseño modular, filtros reutilizables, sistemas energéticamente eficientes y un almacén robotizado totalmente automatizado.
CSL (OTC:CSLLY)는 Broadmeadows, 호주에 있는 혈장 분획 공장이 ISPE가 2025년 10월 26일에 발표한 올해의 최우수 시설로 선정되었다고 밝혔다. 이 맞춤형 공장은 Pharma 4.0 원칙, 고급 자동화, 실시간 모니터링, 로보틱스, 디지털 트윈을 활용해 종이 없는 다 공정 제조의 유연성을 제공한다.
CSL은 이 시설이 혈장 처리 능력을 아홉 배 증가시켜 연간 1,000만 리터 이상을 다룰 수 있게 했다고 보고했고, 모듈식 디자인, 재사용 가능한 필터, 에너지 효율적 시스템, 완전히 자동화된 로봇 창고를 언급했다.
CSL (OTC:CSLLY) a annoncé que son usine de fractionnement du plasma à Broadmeadows, Australie, a été nommée Gagnant global du Prix Facility of the Year 2025 par l'ISPE le 26 octobre 2025. L'usine sur mesure utilise les principes Pharma 4.0, une automation avancée, une surveillance en temps réel, de la robotique et un jumeau numérique pour permettre une fabrication flexible, sans papier, multi-processus.
CSL a déclaré que l'installation a augmenté sa capacité de traitement du plasma de neuf fois pour gérer plus de 10 millions de litres par an, citant un design modulaire, des filtres réutilisables, des systèmes éconergétiques et un entrepôt robotisé entièrement automatisé.
CSL (OTC:CSLLY) sagte, dass seine Plasmaspaltungsanlage in Broadmeadows, Australien, am 26. Oktober 2025 von ISPE zum Gesamt-Sieger des Jahres 2025 erklärt wurde. Die maßgeschneiderte Anlage nutzt Pharma 4.0-Prinzipien, fortgeschrittene Automatisierung, Echtzeitüberwachung, Robotik und einen digitalen Zwilling, um eine flexible, papierlose, multi-prozessierte Herstellung zu ermöglichen.
CSL berichtete, dass die Anlage die Plasmabehandlungskapazität um das Neunfache erhöht habe, um über 10 Millionen Liter pro Jahr zu verarbeiten, und nannte modulare Bauweise, wiederverwendbare Filter, energieeffiziente Systeme und ein vollständig automatisiertes Roboterlager.
سي إس إل (الأوراق المالية OTC: CSLLY) قالت إن منشأة فصل البلازما في Broadmeadows، أستراليا، فازت بـ الفائز العام بجائزة منشأة السنة 2025 منISPE في 26 أكتوبر 2025. تستخدم المنشأة المصممة خصيصاً مبادئ Pharma 4.0، وأتمتة متقدمة، ورصد في الوقت الفعلي، والروبوتات، ونموذجًا رقميًا لتمكين تصنيع متعدد العمليات وبدون ورق.
أفادت CSL بأن المنشأة زادت قدرة معالجة البلازما بمقدار تسعة أضعاف لتتسع لـ أكثر من 10 ملايين لتر سنويًا، وأشارت إلى تصميم modular، فلاتر قابلة لإعادة الاستخدام، وأنظمة موفرة للطاقة، ومستودع روبوتي مؤتمت بالكامل.
CSL (OTC:CSLLY) 表示，其位于澳大利亚 Broadmeadows 的血浆分离工厂于 2025 年 10 月 26 日被 ISPE 评为 年度总冠军，获颁 2025 年年度设施奖。该专用工厂采用 Pharma 4.0 原则、先进的自动化、实时监控、机器人技术和数字孪生以实现灵活的、无纸化的多工艺制造。
CSL 报告称，该设施将血浆处理能力提高了 九倍，可处理 每年超过 1000 万 升，并提到模块化设计、可重复使用的过滤器、节能系统以及一个全自动化的机器人仓库。
- Plasma processing capacity increased nine-fold
- Capacity now handles over 10 million litres annually
- Modular design enables scalability and long-term adaptability
- Advanced automation and digital twin enable paperless, flexible manufacturing
- Sustainable features include reusable filters and energy-efficient systems
- Fully automated warehouse with robotic material handling
- None.
Setting new standards in responsible innovation, CSL's Broadmeadows facility blends Pharma 4.0™ principles with sustainable design to transform plasma manufacturing
BROADMEADOWS,
Purpose-built to optimise the production of plasma-derived therapies for conditions such as immunodeficiencies, neurological disorders, and burns, the Broadmeadows facility combines cutting-edge technologies with a pioneering hybrid manufacturing platform. Key features include advanced automation, real-time production monitoring, robotics, and digital twin infrastructure that enable flexible multi-process manufacturing, fully paperless execution and continuous improvement. Its modular design ensures scalability and long-term adaptability.
These advancements have increased plasma processing capacity nine-fold – enabling the facility to handle over 10 million litres annually – while boosting efficiency and yield, which enables CSL to impact the lives of more patients globally.
"This prestigious award underscores CSL's unwavering commitment to innovation, operational excellence, and sustainability, and positions the Broadmeadows facility as a global benchmark in next-generation biopharmaceutical manufacturing. The Facility of the Year Award is a tribute to the dedication and collaboration of our entire team – across functions and continents," emphasised Andrew Hodder, VP Manufacturing and Site Head at Broadmeadows.
The facility's sustainable infrastructure plays a vital role in advancing CSL's commitment to responsible innovation and long-term impact, with innovations such as reusable filters, energy-efficient systems, and a fully automated warehouse powered by robotic vehicles for seamless material handling. "By combining automation, digital innovation, and sustainable design, we've built a future-ready facility that not only meets the highest standards in pharmaceutical manufacturing but also sets a new benchmark for responsible innovation", underlined Jeffrey Ball, Chief Sustainability Officer and Senior Vice President for EHS, Strategy & Engineering.
This recognition builds on the facility's earlier achievement in May 2025, when it received the ISPE FOYA award in the Pharma 4.0™ category for its advanced use of digital technologies and automation to transform pharmaceutical manufacturing.
About CSL
CSL (ASX: CSL; USOTC: CSLLY) is a leading global biopharma company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our three businesses, CSL Behring, CSL Seqirus and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 29,000+ people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For inspiring stories about the promise of biotechnology, visit CSL.com/Vita
For more information about CSL, visit CSL.com.
Media Contact
In
Jeff Spicer
Mobile: +6 1410974799
Email: Jeff.Spicer@csl.com.au
In
Pia Amend
Mobile: +49 151 25235305
Email: Pia.Amend@cslbehring.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/csl-honoured-as-overall-winner-of-the-2025-facility-of-the-year-awards-by-the-international-society-for-pharmaceutical-engineering-ispe-302594831.html
SOURCE CSL
FAQ
What award did CSL (CSLLY) win for the Broadmeadows facility on Oct 26, 2025?
How much did Broadmeadows' plasma processing capacity increase for CSL (CSLLY)?
What is the annual processing capacity of CSL's Broadmeadows site after the upgrade?
Which Pharma 4.0 technologies did CSL implement at Broadmeadows (CSLLY)?
What sustainability features did CSL highlight for Broadmeadows (CSLLY)?
Had Broadmeadows received prior recognition before the 2025 overall FOYA award?
